Saturday 17 October 2026
Export RANI’s income statement to Excel — free account
Rani Therapeutics Holdings, Inc.
RANI Healthcare Biotechnology
Rani Therapeutics Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.6 million, up 58.9% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS grew 77.8% and free cash flow fell 55.3%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.64
0.04
−5.88%
Follow RANI
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | — | — | 0.00 | 0.00 | 0.00 | — |
Piotroski F-Score |
— | — | — | — | 5 | — | — | — |
Altman Z-Score |
(1.33) | (7.68) | — | — | 72.27 | — | — | — |
P/S ratio |
24.84 | 13.81 | — | — | 113.06 | 75.17 | 75.17 | — |
Altman Z″-Score (non-manufacturers) |
(4.67) | (17.06) | — | — | 51.52 | 8.99 | (26.59) | — |
P/FCF ratio |
0.00 | 0.00 | — | — | 0.00 | 0.00 | 0.00 | — |
P/Operating CF |
303.69 | (4.51) | — | — | (27.90) | (38.53) | (38.53) | — |
P/B ratio |
2.15 | 11.17 | — | — | 2.63 | 0.00 | 0.00 | — |
Price to Tangible BV |
2.15 | 11.17 | — | — | 2.63 | 0.00 | 0.00 | — |
EV/Sales |
15.40 | 12.74 | — | — | 140.48 | 118.71 | 118.71 | — |
EV/EBITDA |
0.00 | 0.00 | — | — | 0.00 | 0.00 | 0.00 | — |
EV/Operating CF |
(2.96) | (1.01) | — | — | (12.31) | (21.80) | (21.80) | — |
EV/FCF |
(2.94) | (1.01) | — | — | (12.12) | (21.14) | (21.14) | — |
Quick Ratio |
4.08 | 1.39 | 6.08 | 20.45 | 44.49 | 14.09 | 4.80 | — |
Current Ratio |
4.21 | 1.50 | 6.36 | 20.96 | 45.30 | 14.12 | 4.84 | — |
Net Debt/EBITDA |
1.33 | 0.06 | 0.28 | 1.07 | 2.30 | 4.34 | (3.73) | — |
Debt/Assets |
0.00% | 67.19% | 50.73% | 27.91% | 0.00% | 4.75% | 501.72% | 0.00% |
Debt/Equity |
0.00 | 7.05 | 1.15 | 0.41 | 0.00 | 0.05 | (1.20) | — |
Asset Turnover |
0.03 | 0.02 | 0.00 | 0.00 | 0.03 | 0.01 | 0.09 | — |
Operating CF/Net income |
0.63 | 1.18 | 1.51 | 1.52 | 3.87 | 0.90 | 0.99 | — |
Capex/Depreciation |
(0.11) | (20.62) | 0.97 | 7.16 | (1.02) | (2.04) | 0.00 | — |
Interest Coverage |
(13.25) | (10.59) | (13.00) | (59.24) | (110.73) | (133.42) | (125.01) | — |
| (131.87%) | (207.48%) | (68.32%) | (31.28%) | (202.50%) | 15.91% | 25.32% | — | |
| (62.30%) | (63.50%) | (40.94%) | (26.34%) | (8.18%) | (32.61%) | (230.97%) | — | |
ROIC |
0.00% | (7,135.17%) | (657.31%) | (698.55%) | (783.89%) | (495.21%) | 0.00% | — |
Return on Tangible Assets |
(71.69%) | (263.29%) | (69.38%) | (29.95%) | (6.85%) | (22.54%) | (148.54%) | — |
Average Days of Receivables |
456.42 | 0.00 | — | — | 0.00 | 1,358.87 | 93.21 | — |
Research and Development Expense of Revenue |
1,237.29% | 2,595.53% | 0.00% | 0.00% | 974.68% | 2,606.93% | 2,510.62% | — |
Selling, General and Administrative Expense of Revenue |
1,208.70% | 2,329.38% | 0.00% | 0.00% | 1,024.44% | 1,074.03% | 296.32% | — |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
722.47% | 1,559.44% | 0.00% | 0.00% | 831.62% | 0.00% | 0.00% | — |
Graham Net Nets |
0.41 | (0.09) | — | — | 0.37 | 0.27 | 0.27 | — |
Graham Number |
0.00 | 0.00 | — | — | 0.00 | 0.00 | 0.00 | — |
Earnings Yield |
(43.70%) | (77.37%) | — | — | (5.08%) | (5.51%) | (5.51%) | — |
Free Cash Flow Yield |
(21.06%) | (91.67%) | — | — | (10.25%) | (7.47%) | (7.47%) | — |
Revenue per Share |
0.02 | 0.04 | 0.00 | 0.00 | 0.14 | 0.02 | 0.05 | — |
Operating CF per Share |
(0.28) | (1.25) | (2.01) | (1.95) | (1.65) | (0.76) | (1.33) | — |
Capex per Share |
0.00 | (0.01) | (0.05) | (0.07) | (0.03) | (0.06) | 0.00 | — |
Free Cash Flow per Share |
(0.28) | (1.26) | (2.06) | (2.02) | (1.68) | (0.82) | (1.33) | — |
Cash per Share |
0.75 | 0.97 | 1.90 | 4.13 | 6.01 | 3.70 | 0.84 | — |
Shareholders Equity per Share |
0.63 | 0.12 | 1.00 | 3.11 | 6.22 | 3.62 | (4.90) | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
0.63 | 0.12 | 1.00 | 3.11 | 6.22 | 3.62 | (4.90) | — |
Free Cash Flow |
(18.80) | (35.76) | (52.46) | (48.13) | (32.75) | (16.16) | (26.27) | — |
Working Capital |
40.65 | 9.85 | 42.86 | 96.11 | 116.96 | 69.64 | 13.45 | — |
Capital Expenditures |
(0.09) | (0.27) | (1.23) | (1.62) | (0.51) | (1.20) | (1.58) | — |
Net Current Asset Value |
36.21 | (3.40) | 18.37 | 66.90 | 116.96 | 66.91 | (102.71) | — |
EV/EBIT |
0.00 | 0.00 | — | — | 0.00 | 0.00 | 0.00 | — |
Capex to Sales |
0.05 | 0.26 | 0.00 | 0.00 | 0.19 | 2.60 | 0.00 | — |
Price to Operating Income |
0.00 | 0.00 | — | — | 0.00 | 0.00 | 0.00 | — |
| Other line items | ||||||||
Depreciation/Fixed assets |
1.13 | 0.01 | (0.21) | (0.04) | 0.11 | 0.13 | 0.13 | — |
Cash ROIC |
(20.61%) | (64.16%) | (50.76%) | (23.75%) | (13.70%) | (10.90%) | (74.19%) | — |
Accounts Receivable Turnover |
0.87 | 0.00 | — | — | 0.00 | 0.47 | 0.99 | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Inventory Turnover |
— | — | — | 0.00 | — | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Days of Inventory on Hand |
— | — | — | 0.00 | — | — | — | — |
Average Receivables |
1.88 | — | — | — | — | 0.99 | 0.99 | — |
Average Payables |
0.83 | 1.00 | 1.05 | 1.27 | 0.81 | 0.37 | 0.37 | — |
Average Assets |
47.63 | 47.28 | 82.97 | 116.12 | 101.81 | 51.22 | 11.51 | — |
Average Common Equity |
22.50 | 14.47 | 49.72 | 97.79 | 4.11 | (104.99) | (104.99) | — |
Columns are period end dates